Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTSGet Rating) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 362,800 shares, an increase of 59.4% from the March 15th total of 227,600 shares. Currently, 3.1% of the shares of the stock are short sold. Based on an average trading volume of 377,800 shares, the short-interest ratio is currently 1.0 days.

In related news, CEO Joseph C. Sardano sold 50,274 shares of the company’s stock in a transaction that occurred on Wednesday, March 9th. The shares were sold at an average price of $10.19, for a total transaction of $512,292.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Javier Rampolla sold 9,000 shares of the company’s stock in a transaction that occurred on Friday, March 4th. The stock was sold at an average price of $9.42, for a total transaction of $84,780.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 114,056 shares of company stock valued at $1,151,818. 24.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in Sensus Healthcare by 83.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 5,500 shares of the company’s stock valued at $40,000 after buying an additional 2,500 shares during the period. HCR Wealth Advisors bought a new stake in shares of Sensus Healthcare during the 4th quarter valued at about $72,000. Sheaff Brock Investment Advisors LLC grew its stake in Sensus Healthcare by 59.8% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 26,714 shares of the company’s stock worth $96,000 after purchasing an additional 10,000 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Sensus Healthcare during the fourth quarter worth approximately $141,000. Finally, Virtu Financial LLC increased its holdings in Sensus Healthcare by 88.2% in the fourth quarter. Virtu Financial LLC now owns 21,756 shares of the company’s stock worth $157,000 after purchasing an additional 10,195 shares in the last quarter. 14.64% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently issued reports on the stock. TheStreet upgraded shares of Sensus Healthcare from a “c” rating to a “b-” rating in a research report on Friday, February 11th. Maxim Group began coverage on shares of Sensus Healthcare in a research report on Friday, February 11th. They issued a “buy” rating and a $12.00 price target for the company. Finally, HC Wainwright upped their price target on shares of Sensus Healthcare from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Thursday, March 3rd.

Shares of NASDAQ SRTS opened at $8.79 on Friday. Sensus Healthcare has a 52-week low of $3.08 and a 52-week high of $11.96. The firm has a 50 day moving average price of $9.93 and a two-hundred day moving average price of $7.49. The stock has a market cap of $146.44 million, a P/E ratio of 36.63 and a beta of 0.30.

Sensus Healthcare (NASDAQ:SRTSGet Rating) last announced its quarterly earnings results on Thursday, February 10th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.18. Sensus Healthcare had a net margin of 15.23% and a return on equity of 18.88%. The firm had revenue of $13.03 million during the quarter, compared to analysts’ expectations of $11.01 million. During the same period in the prior year, the company posted $0.06 EPS. On average, analysts expect that Sensus Healthcare will post 0.3 EPS for the current year.

About Sensus Healthcare (Get Rating)

Sensus Healthcare, Inc manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

See Also

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.